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Wnt signalling has pivotal roles in tumour progression and metastasis; however,
the exact molecular mechanism of Wnt signalling in the metastatic process is as
yet poorly deﬁned. Here we demonstrate that the tumour metastasis suppressor
gene, NDRG1, interacts with the Wnt receptor, LRP6, followed by blocking of the
Wnt signalling, and therefore, orchestrates a cellular network that impairs the
metastatic progression of tumour cells. Importantly, restoring NDRG1 expression
byasmallmoleculecompoundsigniﬁcantlysuppressedthe capabilityofotherwise
highly metastatic tumour cells to thrivein circulation and distantorgans in animal
models. In addition, our analysis of clinical cohorts data indicate that Wntþ/
NDRG /LRPþ signature has a strong predictable value for recurrence-free survival
of cancer patients. Collectively, we have identiﬁed NDRG1 as a novel negative
master regulator of Wnt signalling during the metastatic progression, which opens
an opportunity to deﬁne a potential therapeutic target for metastatic disease.
INTRODUCTION
Cancer is becoming a curative disease due to the screening for
early detection and signiﬁcant advancement of treatment
measures; however, more than 90% of cancer deaths are still
attributed to metastatic disease. Although metastasis has been
considered as a stepwise culmination of neoplastic progression,
recent discoveries from both clinical and experimental studies
indicate that metastatic progression is an independent process
fromprimarytumourdevelopmentandacquisitionofmetastatic
competence can occur at an early stage of tumour progression
(Kim et al, 2009; Klein, 2009; Norton and Massague, 2006;
Riethmu ¨ller and Klein, 2001). Nevertheless, metastasis is a
complex process and needs dysregulation of a series of genes
and related signalling for proliferation, survival, invasion,
angiogenesis and growth at distant sites. Many studies have
demonstrated that characteristic changes of oncogene pathways
for primary tumorigenesis such as Wnt signalling are also
integral parts of the metastatic progression (Khew-Goodall and
Goodall, 2010; Nguyen et al, 2009; Zhang et al, 2009). Wnt
pathwayisanessentialsignallingforembryogenesisandnormal
physiology; however, it also plays a major role in the primary
tumorigenesis and the metastatic progression (Clevers, 2006;
KlausandBirchmeier,2008;Logan andNusse,2004;Moonetal,
2004). Binding of Wnt ligands to its co-receptors, Frizzled and
low density lipoprotein receptor-related protein 5/6 (LRP5/6),
prevents the degradation of b-catenin which then accumulates
in the nucleus and serves as an active transcription factor with
T-cell speciﬁc transcription factor/Lymphoid enhancer-binding
factor (TCF/LEF) followed by activation of various pro-
metastatic genes (Logan & Nusse, 2004). Wnt signalling is also
capable of inducing epithelial-to-mesenchymal transition (EMT),
which plays a critical role in metastatic progression of epithelial
cancers (Vincan & Barker, 2008). Although aberrant expression
of Wnt signalling has been well documented in various cancers,
the exact molecular mechanism by which the dysregulated Wnt
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mation and metastatic progression is as yet poorly understood.
Another important evidence for the notion that metastasis is
distinct from tumorigenesis came from the studies of metastasis
suppressors, which inhibit metastasis but do not affect the
primarytumourgrowth(Bergeretal,2005;Nash&Welch,2006;
Shevde & Welch, 2003; Steeg, 2003, 2006). N-myc downstream
regulated gene-1 (NDRG1) was originally isolated as a novel
gene that was strongly induced during differentiation of colon
carcinoma cell lines (Van Belzen et al, 1997), and it was
shown to be controlled by various neoplastic factors and
microenvironment (Ellen et al, 2008; Kovacevic & Richardson,
2006).Recentstudiesprovidecompelling evidenceshowingthat
the NDRG1 is a tumour metastasissuppressor and its status may
serve as a diagnostic and prognostic marker (Iiizumi et al, 2008;
Kitowska & Pawełczyk, 2010). However, how NDRG1 exerts its
metastasis suppressor function is largely unknown. To gain
mechanistic insight into the role of NDRG1, we took two
different approaches. One is to identify downstream effectors of
NDRG1 by microarray analysis, by which we found that NDRG1
inhibited metastasis by suppressing the expression of activating
transcription factor3 (ATF3) gene, a stress-inducible transcrip-
tion factor (Bandyopadhyay et al, 2006a). Secondly, we
performed a protein–protein interaction screening using yeast
two-hybrid screening system and found that NDRG1 is capable
of interacting with LRP6, a co-receptor of Wnt signalling.
In this report, we investigated the molecular mechanism by
which cross-talk of NDRG1 and Wnt pathways modulates
metastatic process and also explored a possibility of restoring
the NDRG1 expression by small molecule compound as a
potential therapeutic intervention for metastatic disease.
RESULTS
NDRG1 interacts with the Wnt co-receptor LRP6 and blocks
the Wnt-b-catenin signalling
After performing the yeast two-hybrid screening using a
complementary DNA (cDNA) library of normal human prostate
tissues,we found that LRP6 showedthe strongestinteractionwith
NDRG1 (Fig 1A). To verify the interaction of these proteins in
mammalian cells, NDRG1 and LRP6 were tagged with Flag and
HA, respectively. Flag-NDRG1was then subcloned into a tetra-
cycline (Tet) inducible vector followed by establishing a cell line
using PC3mm and MCF7 cells (PC3mm/Tet-Flag-NDRG1 and
MCF7/Tet-Flag-NDRG1, referred to as PC3mm/Tet and MCF7/
Tet). Our results of Co-IP showed that NDRG1 was pulled down
with LRP6 and vice versa, suggesting that these two proteins are
indeed interacting in human prostate cancer cells (Fig 1B,
Supporting Information Fig S1A). We also found that up to 116
bases and 3929 bases from each N-terminal of NDRG and LRP6,
respectively, are dispensable for the interaction (Supporting
Information Fig S1B). Because Wnt is known to induce
phosphorylation of LRP6 at multiple sites (Thr
1479,S e r
1490 and
Thr
1493)(Davidsonet al,2005;Tamai etal,2004;Zengetal,2005)
followedbyactivationofdownstreamsignalling,weexaminedthe
effect ofNDRG1onLRP6 and found that phosphorylation of LRP6
(Ser
1490) induced by Wnt signalling was substantially decreased
by NDRG1, while it did not affect the total protein level of LRP6
(Fig1C),suggestingthatNDRG1interactswithLRP6andprevents
its activation by Wnt ligands. To further examine the effect of
NDRG1 on Wnt signalling pathway, we performed a phospho-site
proﬁling analysis and found that ectopic expression of NDRG1
strongly increased the phosphorylated level of glycogen synthase
kinase3b (GSK3b)( T y r
279/216) and alsode-phosphorylatedAktat
Thr
308, while NDRG1 did not affect their mRNA expression
(Fig 1D, Supporting Information Fig S1C and D). On the other
hand, knocking down of LRP6 alone did not alter the
phosphorylation of Akt, suggesting that NDRG1 can de-phos-
phorylate Akt independently from the Wnt pathway (Supporting
Information Fig S1D). GSK3b is a key signal mediator of the Wnt
pathway, which is constitutively active in the absence of Wnt
ligand and forms a scaffold complex with adenomatous polyposis
coli (APC),axin and CK1atostimulateubiquitinationofb-catenin
for its degradation (Logan & Nusse, 2004; Moon et al, 2004). Wnt
signalling leads to de-phosphorylation of GSK3b to inactivate this
protein followed by stabilization of b-catenin and activation of
downstream targets. It should be also noted that Akt inactivates
GSK3b by phosphorylating it at Serine
9/21 residues (Cross et al,
1995). Therefore, our results suggest that NDRG1 interacts with
LRP6 and blocks silencing signals of Wnt pathway, leading to re-
activation of GSK3b. Furthermore, we performed TopFlash
reporter assay and found that NDRG1 signiﬁcantly blocked
Wnt-induced reporter activity in both prostate and breast cancer
cells, while knocking down of NDRG1 by small hairpin RNA
(shRNA) signiﬁcantly augmented the Wnt reporter activity in
RWPE1whichisanimmortalizedhumanprostatecelllineandhas
a high level of NDRG1 (Fig 1E, Supporting Information Fig S1E).
We also found that induction of NDRG1 signiﬁcantly down-
regulated b-catenin expression (Fig 1F and G). The down-
regulation is likely due to the degradation of this protein because
NDRG1strongly increased phosphorylationofb-catenin at Ser33/
Ser37/Thr41 residues that are the targets of GSK3b for the
subsequent degradation of b-catenin (Supporting Information
FigS1F).TheseresultsstronglyindicatethatNDRG1interactswith
and inactivates LRP6 followed by blocking de-phosphorylated
inactivation of GSK3b and subsequent activation of Wnt
signalling. NDRG1 was previously shown to be down-regulated
by N-myc and C-myc genes that are known targets of Wnt
signalling. Therefore, we examined the expression of NDRG1 in
the presence or absence of Wnt after knocking down N-myc or C-
myc. We found that knock-down of myc genes indeed
signiﬁcantly up-regulated the NDRG1 expression; however,
Wnt treatment signiﬁcantly abrogated this effect (Supporting
Information Fig S1G).Therefore, our resultssuggest that there are
otherinhibitoryfactorsofNDRG1asWntdownstreamtargetsand
that NDRG1 expression is controlled by an intricate balance
between Wnt-mediated expression of NDRG1 inhibitors and
suppressive effect of NDRG1 on the Wnt signalling.
NDRG1 inhibits ATF3 through modulating Wnt-b-catenin
signalling
Previously, we demonstrated that NDRG1 was able to modulate
the metastasis-promoting gene ATF3, and therefore, we further
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Figure 1. NDRG1 interacts with the Wnt co-receptor, LRP6, and blocks Wnt-b-catenin signalling by re-activating GSK3b.
A. NDRG1 was fused with LexA DNA-binding domain at N- or C-terminal, and LRP6 was fused with B42 activation domain. Appropriate combinations of
expressionplasmidsweretransformed inthesameyeaststrainEGY48. Theresultanttransformants weregrownandassayed forthe b-galactosidase activity of
the reporter LacZ gene. pBait and pTarget are a pair of positive controls. Inset image shows transformants grown in an agar plate containing X-gal.
B. Co-IP analysis for the interaction of NDRG1 and LRP6 in mammalian cells. PC3mm/Tet cells were transfected with the expression plasmid of HA-LRP6, treated
with tetracycline to induce NDRG1. Cell lysates were precipitated with anti-HA for LRP6 (lanes 3 and 4) or anti-Flag for NDRG1 (lane 5) followed by Protein-G
agarose. Western blot was performed to detect NDRG1 and LRP6.
C. PC3mm/Tet and MCF7/Tet cells were treated with (lanes 1 and 2) or without (lanes 3 and 4) tetracycline to induce NDRG1 in the presence (lanes 1 and 3) or
absence (lanes 2 and 4) of Wnt. Cell lysates were subjected to Western blot with antibodies against phospo-LRP6, total-LRP6, Flag-NDRG1 and b-tubulin.
D. Western blot analysis to confirm results from phospho-site profiling analysis for phospho-GSK3b (Tyr
279/216), GSK3b, phospho-Akt (Ser
473) and Akt expression
in PC3mm/Tet and MCF7/Tet cells that were treated with or without tetracycline.
E. PC3mm/Tet and MCF7/Tet cells were transfected with the TOPflash reporter plasmid in the presence or absence of Wnt followed by treatment with
tetracycline or not. Luciferase activity of cell lysates was assayed and normalized by internal Renilla luciferase activity. Values are from three independent
experiments in triplicate. p values were calculated by two-sided Student’s t-test.
F. Western blot analysis of b-catenin expression in PC3mm/Tet cells treated with or without tetracycline prior to the addition of Wnt.
G. PC3mm/Tet-Flag-NDRG1 cells were transfected with YFP-b-catenin and RFP expression plasmids in the presence or absence of tetracycline. After 48h, the
fluorescence intensity of b-catenin was determined under a confocal microscope. Each value was normalized by the RFP fluorescence intensity. Right panels
showrepresentativemicroscopicphotosforeachexperimentalgroup.Valuesarefromthreeindependentexperimentsintriplicate. pvalueswerecalculated by
two-sided Student’s t-test.
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signalling. We found that Wnt strongly increased the nuclear
expression of ATF3 and that the induction of NDRG1 strongly
abrogated this effect (Supporting Information Fig S1H). Con-
sistently, ectopic expression of b-catenin and TCF also
signiﬁcantly promoted the expression of ATF3 at both mRNA
and protein levels in prostate and breast cancer cells (Fig 2A).
Moreover, a deletion of b-catenin/TCF binding consensus
sequence of the ATF3 promoter signiﬁcantly blocked the
suppressive effect of NDRG1 (Fig 2B), suggesting that
down-regulation of ATF3 by NDRG1 depends directly on the
b-catenin/TCF binding site in the ATF3 promoter. In agreement
with this result, we found that Wnt treatment led to a signiﬁcant
increase in the ATF3 promoter activity of wild type but not
mutant (Fig 2C), and that Wnt substantially augmented the level
of ATF3 protein which was decreased upon induced NDRG1
expression (Fig 3B). In addition, our results of ChIP assay by
precipitating b-catenin/TCF-chromatin complex clearly showed
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Figure 2. NDRG1 blocks Wnt-b-catenin signalling followed by inhibiting ATF3 expression.
A. The expression of ATF3 was examined by qRT-PCR or ATF3 reporter assay in PC3mm (left panel) or MCF7 (right panel) that were transfected with or without
the expression plasmid of b-catenin/TCF. Western blot was also performed to confirm the ATF3 expression in the presence of b-catenin/TCF. Values are from
three independent experiments in triplicate.
B-C. Three-base mutation was introduced into the consensus sequence of b-catenin/TCF binding site on the ATF3 gene promoter of the CAT-reporter plasmid.
Wild-type and mutant reporter plasmids were then transfected into PC3mm/Tet or MCF7/Tet cells in the presence or absence of tetracycline (B) or Wnt (C).
CAT activity of the cell lysates was assayed and normalized by internal Renilla luciferase activity. Western blot analysis of ATF3 expression was also
performed. Values are means SD of triplicate measurements.
D. ChIP assay for PC3mm/Tet cells treated with or without tetracycline for 48h. Precipitated DNA was subjected to q-PCR using primers specific for the
b-catenin binding consensus sequence on the ATF3 promoter (F1R1) as well as a control primer set (F2R2). The ratio of the precipitated DNA was calculated
based on cyclic threshold value for each reaction. Values are means SD of triplicate measurements. For all experiment, p values were calculated by
two-sided Student’s t-test.
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promoter, while expression of NDRG1 led to more than 95%
decrease in binding efﬁciency (Fig 2D), which provided direct
evidence that NDRG1 suppresses ATF3 expression by blocking
Wnt-b-catenin signalling.
NDRG1 suppresses Wnt/b-catenin-induced mesenchymal
traits and metastatic-relevant activities
Because Wnt/b-catenin signalling affects various stages of
tumour progression, we next examined the effect of NDRG1 on
metastasis cascade through blocking the Wnt signalling. We
found that over-expression of NDRG1 did not affect cell viability
in monolayer culture; however, it signiﬁcantly suppressed the
colony-forming ability of tumour cells under the anchorage-
independent condition (Supporting Information Fig S2A),
suggesting that NDRG1 affects invasiveness and outgrowth of
tumour cells when they inﬁltrate into distant organs. The Wnt-
b-catenin signalling also plays a critical role in the EMT, a
process vital for endowing malignant tumour cells to acquire
motility and invasive as well as survival abilities during
dissemination (Polyak and Weinberg, 2009). We found that
an addition of Wnt to PC3mm/Tet cells, which normally
exhibited a characteristic epithelial cobblestone-like morphol-
ogy, converted them to be more ﬁbroblastic morphology
whereas induction of NDRG1 expression partially reverted
these cells to epithelial morphology (Fig 3A). This morpholo-
Research Article
Wen Liu et al.
A B
Wnt -
N
D
R
G
1
-
N
D
R
G
1
+
Wnt +
PC3mm/Tet/Drg1
Wnt
Tet-NDRG1 - - +       +
- +       - +
E-cadherin
β-Tubulin
ATF3
Wnt
Tet-NDRG1 -
- +
-
-
++
+
β
c
a
t
e
n
i
n
D
A
P
I
M
E
R
G
E
C
Vimen n
E-cadherin
NDRG1
R
W
P
E
1
H
P
V
1
0
H
P
V
7
P
W
R
1
E
P
C
3
D
U
C
a
P
V
C
a
P
L
N
C
a
P
W
P
M
Y
1
W
9
9
D
U
1
4
5
R
W
P
E
2
M
D
A
P
C
a
2
b
Vimen n
E-cadherin
NDRG1
Fibronec n1
L
Y
2
B
T
2
0
M
D
A
M
B
1
7
5
M
D
A
M
B
4
6
8
M
D
A
M
B
1
3
4
M
D
A
M
B
1
5
7
H
S
5
7
8
T
M
C
F
1
0
A
H
C
C
1
5
6
9
H
B
L
1
0
0
B
T
5
4
9
S
U
M
1
5
9
P
T
H
C
C
3
8
M
D
A
M
B
2
3
1
S
U
M
2
2
5
C
W
N
S
U
M
5
2
P
E
6
0
0
M
P
E
S
U
M
1
8
5
P
E
M
C
F
7
M
D
A
M
B
3
6
1
H
C
C
1
9
3
7
H
C
C
1
4
2
8
B
T
4
7
4
H
C
C
2
1
5
7
H
C
C
1
1
4
3
B
T
4
8
3
S
U
M
1
9
0
P
T
H
C
C
1
0
0
7
S
U
M
1
4
9
P
T
H
C
C
3
1
5
3
H
C
C
2
0
2
D
0
0.1
0.2
0.3
0.4
0.5
 
F
i
b
r
o
n
e
c
t
i
n
 
m
R
N
A
 
(
R
L
U
)
Wnt
Tet-NDRG1
-
-
+ - ++
- +
0
0.25
0.50
0.75
1.00
1.25
1.50
1.75
Wnt
Tet-NDRG1
-
-
+ - ++
- +
S
l
u
g
 
m
R
N
A
 
(
R
L
U
)
0
0.5
1.0
1.5
2.0
Wnt
Tet-NDRG1
-
-
+ - + +
- +
 
V
i
m
e
n
t
i
n
 
m
R
N
A
 
(
R
L
U
)
0
0.5
1.0
1.5
2.0
Tet-NDRG1 - +
 
T
w
i
s
t
 
m
R
N
A
 
(
R
L
U
)
P=0.0017 P=0.0223
P=0.0254
P=0.0003 P=0.0001 P=0.0019 P=0.0047
Flag-NDRG1
Wnt- Wnt+ Wnt- Wnt+
Tet-NDRG1- Tet-NDRG1+
Figure 3. NDRG1 suppresses Wnt-mediated EMT.
A. EMT-like morphological changes of PC3mm/Tet cells that were treated with or without Wnt in the presence or absence of tetracycline.
B. Western blot analysis for E-cadherin and ATF3 expression (left panel) and immuno-fluorescence staining of b-catenin (right panel) in PC3mm/Tet cells that
were treated with or without tetracycline prior to the addition of Wnt.
C. PC3mm/Tet-Flag-NDRG1 cells were cultured in the presence or absence of Wnt with or without the treatment of tetracycline. RNA were then prepared and
subjected to qRT-PCR analysis for the expression of Slug, Fibronectin, Vimentin and Twist. Values are from three independent experiments in triplicate. p values
were calculated by two-sided Student’s t-test. Western blot analysis was also performed to confirm the expression of NDRG1 (inserted fig).
D. NDRG1 expression correlates with epithelial traits in a panel of prostate (left panel, GSE9633) and breast (right panel, Neve et al, 2006) cancer cell lines.
Heatmap depicts the relative expression of normalized expression values of E-cadherin, NDRG1, Fibronectin1 and Vimentin for each cell lines. Green colour
indicates low expression and red colour indicates high expression. Representative cell lines exhibiting epithelial-like and mesenchymal morphologies were
marked with red and green colours, respectively.
www.embomolmed.org EMBO Mol Med 4, 93–108  2012 EMBO Molecular Medicine 97gical change was accompanied by up-regulation of E-cadherin
and membrane b-catenin (Fig 3B),as wellas down-regulation of
EMT-regulatory factors Slug, Twist, Vimentin and Fibronectin
(Fig 3C). Besides its role as a hub of Wnt-mediated transcrip-
tional events, b-catenin at the cytoplasmic membrane serves as
a core component of cadherin–catenin adherent junctions
between adjacent epithelial cells (Heuberger and Birchmeier,
2010).AsshowninFig3B(rightpanel),weindeedobservedthat
Wnt treated cells showed relocalization of b-catenin from
cytoplasm to nucleus compared with the non-treated control
cells;however,inductionoftheNDRG1expressionsubstantially
decreased cytoplasmic/nuclear b-catenin, suggesting that
NDRG1 re-activates GSK3b, thereby promoting proteasome-
mediated degradation of cytosol b-catenin. We also found that
NDRG1 suppressed Wnt-induced mesenchymal traits in MCF7/
Tet cells (Supporting Information Fig S2B-E). Moreover, we
demonstrated that high expression of NDRG1 gene was
positively correlated with the expression of E-cadherin but
not with Vimentin in a panel of prostate and breast cancer cell
lines, reﬂecting the correlation of NDRG1 expression with
epithelial phenotype (Fig 3D). These data indicate negative
regulatory role of NDRG1 in EMT process through modulation
of Wnt signalling, which partly account for the metastasis
suppressor function of NDRG1. As shown in Fig 4A, the
activation ofWntsignallingledtomorethanfourfoldincreasein
the invasivenesss of PC3mm/Tet cells, which was signiﬁcantly
blocked by NDRG1 expression. Notably, majority of NDRG1-
expressing cells showed cortical actin distribution whereas
Wnt-treated cells showed condensed stress ﬁbres and
invadopodia-like structures around the periphery of cells
(Supporting Information Fig S2F). We also found that
PC3mm/Tet cells cultured in suspension exhibited anoikis-
mediated cell death; however, addition of Wnt signiﬁcantly
enhanced cell viability, while NDRG1 expression restored the
occurrence of anoikis (Fig 4B). Beside the intrinsic ability to
evade anoikis, metastatic tumour cells also have an ability of
adhering to endothelial cells which provides critical support for
survival during dissemination. We found that, when PC3mm/
Tet cells were co-cultured with mouse lung microvessel
endothelial cells, Wnt treatment signiﬁcantly increased the
number of PC3mm/Tet cells to the endothelial cells by more
than threefold compared to the non-treated cells whereas the
ectopic expression of NDRG1 signiﬁcantly decreased the
number of attached cells even in the presence of Wnt
(Fig 4C, left panel). Furthermore, consistent with the notion
that NDRG1 expression is correlated with epithelial cell type, we
found that NDRG1-expressing cells attached to endothelial cells
showed apparently more differentiated phenotype with tight
intracellular adhesion (Fig 4C, right panel).
Because the abilities of invasion, anoikis-resistance and
adhesion are all essential propensities of disseminating tumour
cells in early stage of metastasis, we speculated that NDRG1ex-
ertsitsmetastasissuppressorfunctionbyblockingtheseabilities
of tumour cells thereby restricting them to thrive in distant sites.
Totestthispossibility,PC3mm/TetcellswithorwithoutNDRG1
expression were labelled with cell-tracker dye and they were
intravenously injected into Nude mice. We found that tumour
cells quickly lodged onto lung endothelium after 2h regardless
of the status of NDRG1 expression (Supporting Information
Fig S2G). However, 48h after implantation, the number of
NDRG1-expressing tumour cells in the lungs was signiﬁcantly
diminished by 60% compared with cells without induction of
NDRG1 expression, and they were detected exclusively within
vessels as a single cell (Fig 4D). Forced activation of Wnt
signalling by ectopic expression of b-catenin and TCF
signiﬁcantly enhanced survival of the tumour cells in the lungs,
butitfailedtoovercomethesuppressiveeffectofNDRG1.Taken
together, our observations from assessing multiple processes of
the metastasis cascade provide compelling evidence that
NDRG1, by modulating Wnt pathway, imposes a metastasis-
suppressive network.
Ability to modulate Wnt signalling is essential for NDRG1 to
suppress metastasis in vitro and in vivo
To address the question whether the ability of NDRG1 to inhibit
metastasis depends on its ability to modulate Wnt signalling, we
employed the MMTV-Wnt mouse model. The mouse carries the
Wnt transgene which is driven by the mouse mammary tumour
virus LTR and develops extensive ductal hyperplasia early in life
and mammary adenocarcinoma later (Li et al, 2000). We ﬁrst
isolated tumour cells from the mammary tumour of this mouse
and established a cell line (WB1-1) which was then infected with
lentivirus encoding luciferase gene (Supporting Information
Fig S3A). By introducing a Flag-tagged NDRG1 expression vector
and/or a dominant active b-catenin (the DN90 non-degradable
mutant, Bahmanyar et al, 2008) into WB1-1, we further
established a series of WB1-1 cell lines (WB1-1/NDRG1, WB1-
1/DN90-b catenin and WB1-1/DN90-b catenin/NDRG1, referred
to as NDRG1, DN90, DN90/NDRG1). Consistent with our results
of prostate cancer cells, WB1-1cells expressing NDRG1 (WB1-1/
NDRG1) showed drastically decreased level of b-catenin and
ATF3 (Supporting Information Fig S3B), and signiﬁcantly down-
regulated Wnt signalling activity as well as compromised
metastatic abilities compared to the parental WB1-1 cells
(Supporting Information Fig S3C-H). Strikingly, however,
WB1-1 cells with constitutively active b-catenin (DN90 and
DN90/NDRG1) exhibited similar, if not more aggressive abilities
of migration, anoikis resistance, adhesion as well as survival in
the lungs despite over-expression of NDRG1. These data further
support our notion that NDRG1 exerts its metastasis suppressor
activity by inhibiting Wnt signalling.
We next implanted WB1-1 cell series into the mammary fat
pads of SCID mice and monitored the primary and metastatic
tumour growth for 6 weeks. Consistent with the results of our
in vitro study, all cell lines formed primary tumours with
similar growth rate and histological morphology; however, they
exhibited vastly different metastatic behaviors (Fig 5A and B,
Supporting Information Fig S4A). Despite the same rate of
metastatic incidence, mice inoculated with DN90-expressing
cells (N90 and N90/NDRG1) developed distant metastases at a
much earlier stage compared to the parental WB1-1 cells (Fig 5A
and D left panel, Supporting Information Fig S4B), and they also
formed signiﬁcantly larger metastatic lesions (Fig 5C, D right
panel). These observations indicate that constitutively active
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98  2012 EMBO Molecular Medicine EMBO Mol Med 4, 93–108 www.embomolmed.orgb-catenin augmented the Wnt signalling, which promoted
tumour cells to invade from local site and to inﬁltrate into
distant organs followed by colonization. On the other hand,
NDRG1-exression did not affect the primary tumour growth but
suppressed the local invasion and signiﬁcantly reduced overall
metastasis by 80% compared to the parental cells, which is in
accordance with our previous observations in an animal model
of prostate cancer (Bandyopadhyay et al, 2003) (Fig 5A and B,
Supporting Information Fig S4C). However, the metastasis-
suppressive effect of NDRG1 was drastically overcome by
constitutively active b-catenin, which provided direct evidence
that the ability to antagonize Wnt-b-catenin signalling is
required for NDRG1-mediated metastasis suppression. We
further assessed the status of Wnt signalling in primary tumours
by immunostaining for b-catenin and its downstream target
ATF3. As expected, b-catenin was found to be mostly localized
Research Article
Wen Liu et al.
A
Wnt - + - +
0
100
200
300
400
500
600
700
800
R
e
l
a
 
v
e
 
n
u
m
b
e
r
 
o
f
 
 
 
 
 
i
n
v
a
s
i
o
n
 
c
e
l
l
s
 
Tet-NDRG1 - + - +
P=0.0331
P=0.0027 P=0334
0
50
100
150
200
250
300
350
400
450
500
550
Tet-NDRG1
Wnt
- +
- +
-
-
+
+
N
o
.
 
o
f
 
t
u
m
o
r
 
c
e
l
l
s
 
 
a
 
a
h
c
e
d
 
t
o
 
 
E
C
s
P=0.0003
P=0.0002 P=0.0002 C
B
Flag-NDRG1 Flag-NDRG1
-
β
c
a
t
e
n
i
n
/
T
C
F
β
c
a
t
e
n
i
n
/
T
C
F
-
+
0
50
100
150
200
250
Tet-NDRG1 - + - +
N
o
.
 
o
f
 
c
e
l
l
s
/
ﬁ
e
l
d
P=0.0001
P<0.0001
D
-
Tet-induced NDRG1
W
n
t
-
W
n
t
+
- + - +
30 mins 36 hrs
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
Tet-NDRG1
Wnt
- +
-
-
-
+
+
A
n
o
i
k
i
s
 
r
e
s
i
s
t
a
n
c
e
 
 
(
R
e
l
a
 
v
e
 
U
n
i
t
)
P=0.0001
P<0.0001 P<0.0001
+
Figure 4. NDRG1 suppresses Wnt-mediated multiple metastatic traits.
A-C. PC3mm/Tet cells were treated with or without Wnt followed by treatment of tetracycline or not, and were subjected to assays for invasion (A), anoikis
resistance (B) and adhesion assays (C).
D. PC3mm/Tet cells were transfected with the expression plasmids of b-catenin/TCF or vector control plasmids followed by treatment of tetracycline or not.
Cells were then stained with CellTracker Green and injected into the lateral vein of nude mice (n¼3). Lungs were removed after 48h and sectioned followed
by counting the number of tumour cells under the confocal microscope. Lung vasculature was visualized by staining with rhodamine-conjugated lectin. For
all experiment, values are from three independent experiments in triplicate. p values were calculated by two-sided Student’s t-test.
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Figure 5. NDRG1 suppresses metastasis by blocking Wnt pathway in vivo.
A. Totest tumorigenic andmetastatic ability of WB1-1cell lines, 5 10
5cells ofeach line wereinjected intothemammary fat padofnude mice.Non-invasive BLI
was performed to monitor theprimary tumour growth and the development of metastasis. At thetime of necropsy, lungs and bones from individual mice were
dissected and imaged ex vivo for bioluminescence. Shown are representative bioluminescent images of primary tumour and metastasis of individual mice
(n 9).
B. Summary of the tumour size and metastatic incidence at day 43.
C. H&E-stainedsections of mouse lungsfrom each group attheendpoint (left panel).The scale barrepresents100mm. Metastatic growth oftumours in the lungs
was also measured by BLI after necropsy (right panel). Data are presented as the mean photon flux. Error bars represent the SEM. p values were calculated by
two-sided Student’s t-test.
D. Incidence of hind limb bone metastasis was represented by Kaplan–Meier curves, and their metastatic growth was measured by BLI. p values were calculated
by Log-rank test and two-sided Student’s t-test.
E. Immuno-fluoresence staining of b-catenin and ATF3 in mouse primary tumours. The percentage of ATF3 positive tumour cells were quantified for each group.
p values were calculated by two-sided Student’s t-test.
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tumour which was accompanied with minimally detectable
level of ATF3. On the contrary, DN90-expressing tumours
showed robust expression of cytoplasmic/nuclear b-catenin as
well as ATF3 (Fig 5E). Notably, most ATF3 was found at the
margins of the invasive front in primary tumours formed by
DN90-expressing cells, which provided further evidence for a
role of ATF3 in promoting invasion and metastasis (Supporting
Information Fig S4D).
Correlation of NDRG1 with Wnt signalling and metastatic
status of cancer patients
To corroborateour in vitroresultsin clinical settings, expression
of NDRG1, b-catenin and ATF3 were examined by immuno-
histochemistry with tumour specimens from 29 prostate and 33
breast cancer patients. As shown in Fig 6A and B, NDRG1was
strongly expressed in normal prostate and breast epithelium but
was signiﬁcantly down-regulated in high-grade cancers. The
expression of b-catenin was mostly localized in membrane/
cytoplasm in normal tissue, but it was shifted to cytoplasm/
nucleus in high grade tumours. Moreover, positive correlations
between membranous b-catenin and NDRG1 as well as
cytoplasmic/nuclear b-catenin and ATF3 were observed, which
is consistent with the notion that NDRG1 suppresses ATF3
expression by blocking Wnt-b-catenin signalling. We also
examined the expression of NDRG1 and b-catenin in prostate
(n¼52) and breast (n¼66) tissue microarrays including
normal, malignant or metastatic tissues. As shown in
Supporting Information Fig S5A, expressions of NDRG1 and
membrane b-catenin were signiﬁcantly down-regulated in
prostate and breast cancers. Moreover, membranous b-catenin
and NDRG1were positively correlated in both cancers (Support-
ing Information Fig S5B).
To examine whether expression of these genes predicts
clinical outcomes, we analyzed existing multiple cohort data
sets of prostate cancer in GEO database. We found that the
expression of the genes for LRP6, ATF3 and various Wnt ligands
were all signiﬁcantly up-regulated in patients with metastatic
disease compared to those without metastasis (Fig 6C, Support-
ing Information Fig S5C and D). Notably, tissue from distant
metastases showed even higher expression of Wnt than that
from primary tumours (Supporting Information Fig S5C and D,
left panel). In contrast, NDRG1 expression was signiﬁcantly
down-regulated in metastatic tumours and in distant metastatic
sites. These results suggest a multifaceted role of Wnt signalling
in promoting cancer metastasis, which can be achieved by the
loss of NDRG1 expression. Moreover, we found that patients
positive for Wnt or negative for NDRG1 had signiﬁcantly worse
prognosis of metastasis-free survival than their counterpart
(Supporting Information Fig S5D, lowert panels). To further
examine the prognostic value of these markers, we stratiﬁed
prostate cancer patients into different risk groups based on a
combined gene signature (Wnt/LRP6/NDRG1) and analyzed for
theirrelapse-freesurvival.TheresultsofCoxregressionanalysis
showed that patients in the high- (Wntþ/NDRG1  or LRP6þ/
NDRG1 ) and medium-risk (Wnt /NDRG1 ,W n t þ/NDRG1þ,
LRP6 /NDRG1  orLRP6þ/NDRG1þ) groupshad a signiﬁcantly
increased risk of recurrent disease compared to the patients
in the low-risk group (Wnt /NDRG1þ, LRP6 /NDRGþ,
Fig 6D).
A small compound restored NDRG1 expression and blocked
the metastatic ability of human breast cancer cells in vivo
We next explored the possibility that restoration of NDRG1
expression may prevent metastasis in vivo. Dp44mT is a highly
selective agonist of NDRG1 which enhances NDRG1 mRNA and
protein expression (Le & Richardson, 2004; Whitnall et al,
2006).ToevaluateanefﬁcacyofDp44mTontumourmetastasis,
we ﬁrst examined the effect of Dp44mT on the expression of
NDRG1 in culture and found that Dp44mT treatment signiﬁ-
cantly up-regulated NDRG1 by 12–800-fold in mouse (WB1-1)
and human cancer cells (MDA-MB231-BoM and PC3mm), while
it did not affect the expression in cells carrying the silencing
shRNA for NDRG1 (Fig 7A, Supporting Information Fig S6A
and C). Consequently, the reactivation of NDRG1 by Dp44mT
restored membrane expression of b-catenin followed by
suppression of migration and invasion of the tumour cells
(Fig 7B, Supporting Information Fig S6B and C). We then
evaluated the efﬁcacy of Dp44mT in mice by intracardially
injecting human bone metastatic breast cancer cells MDA-
MB231-BoM, followed by a short- and long-period of Dp44mT
treatment. We found that, at day 9, mice that received only four
treatments of Dp44mT showed dramatically reduced circulating
tumour cell burden by 85% compared with those that received
saline (Fig 7C). Extended treatment of Dp44mT for a period of
4 weeks signiﬁcantly blocked the incidence and growth of
distant bone metastasis without apparent toxicity to the mice
(Fig 7D left panel). Importantly, as shown in Fig 7D (middle and
right panels), the knock-down of NDRG1 expression in
MDA-MB231-BoM cells signiﬁcantly blocked Dp44mT-induced
metastasis suppression, suggesting the high selectivity of
Dp44mT Taken together, our results suggest the potential
utility of Dp44mT as an agent to prevent and inhibit metastasis
disease.
DISCUSSION
Aberrant activation of Wnt pathway is known to be linked to
both tumorigenesis and progression of various types of human
cancers (Clevers, 2006; Klaus and Birchmeier, 2008; Logan and
Nusse, 2004; Moon et al, 2004); however, the role of Wnt
signalling in a clinical setting is rather complex and appears
to be dependent on types and stages of tumours. Atypical
expression of Wnt signalling has been observed at relatively
early stages and plays oncogenic roles in colorectal, liver and
pancreatic cancers (Doucas et al, 2005; Hoshida et al, 2009;
Whittakeretal,2010), whileithasbeenfoundtobesigniﬁcantly
correlated with poor prognosis of metastatic tumours in
prostate, breast and lung cancers (Bismar et al, 2004; De la
Taille et al, 2003; Dolled-Filhart et al, 2006; Lo ´pez-Knowles
et al, 2010). Of note is that the nuclear expression of
b-catenin at an early stage is a relatively rare event in prostate
and breast cancers (Arenas et al, 2000; Bismar et al, 2004; De la
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Figure 6. Clinical relevance of NDRG1, b-catenin and ATF3 in prostate and breast cancers.
A. Paraffin block sections of prostate (n¼29) and breast (n¼33) cancer specimens from patients were subjected to IHC analysis using antibodies to NDRG1 and
b-catenin. Upper and lower panels show normal grade and high-grade tumours, respectively. Right panel; correlations of NDRG1 and b-catenin expression
were calculated by the x
2 test.
B. IHC analysis was performed for the same set of prostate cancer specimens to determine the association of ATF3 with NDRG1and b-catenin as well as the
patient metastatic status.
C. Expression of NDRG1 and Wnt-related factors in prostate cancer patients were determined using the Lapointe cohort (GSE3933). p values were calculated by
Mann–Whitney t-test.
D. Kaplan–Meier survival analysis to determine the diagnostic value of the combined Wnt, LRP6 and NDRG1 in the database of Yu cohort (GSE6919). The
relevance to relapse-free survival of patients was assessed by calculating relative hazard ratio and log rank p-value.
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Figure 7. Reactivation of NDRG1 expression by Dp44mT suppresses bone metastasis of human breast cancer cells in vivo.
A-B. WB1-1 cells with or without shRNA for NDRG1 were treated with Dp44mT or vehicle alone. NDRG1 mRNA expression was measured by qRT-PCR (A), and
the motility and invasive abilities of tumour cells were also examined (B). Values are from three independent experiments in triplicate. p values were
calculated by two-sided Student’s t-test.
C. 231-BoM cells (5 10
4) were inoculated into SCID mice by i.c. injection, followed by i.v. administration of Dp44mT (0.4mg/kg) (n¼8) or saline (n¼10) for
four consecutive days. The degree of clearance of the tumour cells in the mice was measured by BLI at day 9. Right panels show representative images of BLI
at day 0 and 9. p values were calculated by two-sided Student’s t-test.
D. 231BoMcells (1 10
5) were inoculated into nude mice through intracardiac injection followed by the treatment with Dp44mT (0.4mg/kg) (n¼10) or saline
(n¼12) for five consecutive days, and the treatment was repeated 4 times with 2 days interval. The left panel indicates metastasis-free survival of the hind
limb of mice. p values are based on Log-rank test. Middle and right panels: 231BoM/shNDRG1 and 231BoM/shScramble cells (1 10
5) were inoculated into
nude mice through intracardiac injection followedby the Dp44mT treatment (0.4mg/kg, n¼12) as above. The middle panel shows thestrength of BLI signal
of bone metastasis. Data are presented as the mean photon flux, error bars represent the SEM. p values were calculated by two-sided Student’s t-test. The
right panel indicates metastasis-free survival of mice. p values were calculated by Log-rank test.
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2010; Lo ´pez-Knowles et al, 2010). Recently, Nguyen et al have
shown that Wnt-b-catenin signalling speciﬁcally promoted
brain and bone metastasis of human lung adenocarcinoma
while it did not affect primary tumour growth (Nguyen et al,
2009). Their results are consistent with the clinical observation
that aberration of Wnt signalling in lung adenocarcinoma is
relatively infrequent (Ding et al, 2008; Sharma et al, 2007), and
therefore, Wnt likely contributes to metastatic progression
rather than initial tumorigenesis. In another study, DiMeo et al
(2009) have identiﬁed Wnt signalling as a lung metastasis
signature to predict the outcome of breast cancer patients. Both
studies showed that Wnt signalling had little effect on
proliferation and viability of cancer cells, while it signiﬁcantly
promoted metastatic phenotypes of cancer cells including self-
renewal, EMT and chemotactic invasion. In our model of WB1-1
cell, blocking Wnt signalling by NDRG1 led to drastic
suppression of metastatic phenotypes of this cell line both in
vitro and in vivo, while it did not affect cell growth in culture or
in animals. Previous studies showed that strong activation of
Wnt signalling, besides its well-known role in carcinogenesis,
was signiﬁcantly correlated with tumour stages and metastasis
in colorectal cancer (Fodde et al, 2001; Inomata et al, 1996).
In particular, Wnt-b-catenin downstream factors, BAMBI (bone
morphogenetic protein and activin membrane-bound inhibitor)
and S100A4/metastasin, was found to promote spontaneous
metastasis of colorectal cancer cells in vivo (Fritzmann et al,
2009; Stein et al, 2006), and the expression of these two effector
genes have been shown to predicts metastasis potential of colon
cancer (Fritzmann et al, 2009; Sherbet, 2009; Togo et al, 2008).
On the other hand, the proto-oncogene, Bcl9 promotes nuclear
translocation of b-catenin followed by increased transcriptional
activation of BAMBI (Fritzmann et al, 2009; Mani et al, 2009).
These results suggest that activation of Wnt signalling leads
to two distinct pathways to induce initial tumorigenesis or
metastatic progression depending on the different transcrip-
tional output of Wnt signal in a cell context dependent manner.
It is considered that different Wnt downstream targets display
differential sensitivity to the upstream b-catenin/TCF, which
may tilt the balance of Wnt signalling in controlling tumour
growth and metastasis. Therefore, our results that NDRG1
suppressedmetastasis without affecting primarytumour growth
may reﬂect the intrinsic regulatory mechanism by which Wnt
signalling controls tumorigenesis and metastasis that are two
distinct processes during tumour progression.
In prostate and breast cancers, loss of NDRG1 expression has
been consistently linked to tumour progression and metastasis
status as well as poor survival of cancer patients (Ellen et al,
2008; Kovacevic and Richardson, 2006). We previously showed
that NDRG1 blocked metastasis in an animal model and that
this suppressor effect is mediated by modulating ATF3, which
functions as a strong pro-metastatic transcription factor
(Bandyopadhyay et al, 2006a,b). Here, we found that ATF3 is
the direct target of b-catenin and that activation of Wnt
signalling signiﬁcantly augmented its expression. Notably,
ATF3 is known to activate EMT-inducing factors, Slug and
Twist (Yin et al, 2008), and we found that they were indeed
activated by Wnt signalling; however, this activation was
signiﬁcantly blocked by NDRG1. Interestingly, Yan et al (2011)
recently showed that ATF3 acts as an oncogene to drive the
mouse mammary tumorigenesis by activating Wnt-b-catenin
signalling, suggesting a positive feedback regulation of Wnt-b-
catenin-ATF3 axis. On the other hand, the NDRG1-mediated
Wnt suppression restored epithelial cell–cell adhesion complex
(E-cadherin-b-catenin),whoseintegrityisessentialforepithelial
cell morphology, polarity and motility (Heuberger and Birch-
meier, 2010). NDRG1 expression was indeed found to be
signiﬁcantly associated with more differentiated and epithelial
phenotype of prostate and breast cancer cells. Therefore,
NDRG1 exerts its metastasis suppressor ability by blocking Wnt
signalling, followed by down-regulation of ATF3, as well as
restoring intracellular adhesion of tumour cells, which blocks
the EMT process and abrogates subsequent acquisition of
metastatic capabilities by tumour cells.
Consistent with the role of Wnt signalling in prostate and
breast cancer progression (Bismar et al, 2004; Dolled-Filhart
et al, 2006; Lo ´pez-Knowles et al, 2010), we observed
signiﬁcantly enhanced expressions of Wnt components in these
cancer patients at advanced stages, which further strongly
linked Wnt with tumour progression and poor clinical out-
comes. Importantly, we found that a combination of NDRG1,
Wnt ligands and LRP6 can be used to predict relapse-free
survival in prostate cancer patients, and that a combination of
Wnt ligands, LRP6 and ATF3 had a signiﬁcant inverse
correlation with metastasis-free survival of breast cancer
patients. Therefore, these signatures would be useful diagnostic
markers to determine the treatment course of patients with
metastatic disease. Finally, because blocking any step of the
metastasis cascade is believed to effectively prevent metastasis,
restoring the expression of negative regulators of metastatic
process such as NDRG1 is an attractive option for therapeutic
intervention. We have shown that Dp44mT was capable of
reactivating NDRG1 expression in metastatic tumour cells and
blocking their invasive ability. Importantly, administration of
Dp44mT signiﬁcantly suppressed the systemic spread of tumour
cells and the incidence of distant metastasis in our animal
modelswithoutshowingnotabletoxicity.Therefore,Dp44mTin
combinationwithotherWntpathwayinhibitorsmayserveasan
effective regimen for prevention and therapy for metastatic
disease.
MATERIALS AND METHODS
Yeast two-hybrid screening
A full-length cDNA of NDRG1 was cloned into the yeast vector
pEG202-NLS (Origene Technologies) as a bait, the yeast two-hybrid
screening was carried out using a cDNA library of normal human
prostate tissue followed by performing a mating assay according to
the manufacturer’s protocol.
Quantitative b-Galactosidase assay
b-Galactosidase assay (Miller test) was performed as previously
described (Bandyopadhyay et al, 2006a,b).
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Human prostate cancer cell line PC3mm was kindly provided by Dr. I. J.
Fidler (The University of Texas M. D. Anderson Cancer Center. Houston.
TX). Human breast cancer cell line MCF7 was obtained from American
Type Culture Collection (Manassas, VA). The PC3mm/Tet cell line was
established previously as a derivative of PC3mm and contains a
tetracycline-inducible suppressor. MCF7/Tet cell line was established
by a similar method. Mouse mammary tumour cells were isolated
from the mammary adenocarcinoma of MMTV-Wnt1 mice using a
similar procedure as previously described (Orimo et al, 2000). L/Wnt3a
cells and mouse lung microvasculature endothelial cells (mLMVECs)
were obtained from ATCC. HEK293/TOP Flash cells carrying a
TOPFlash reporter were established in our lab. All cells were
maintained in RPMI 1640 medium supplemented with 10% foetal
calf serum, streptomycin (100mg/ml), penicillin (100U/ml) and
250nM dexamethasone (Sigma Chemical Co., St. Louis, MO) and
grown at 378C in a 5% CO2 atmosphere. For all transfection
experiments, LipofectAMINE 2000 (Invitrogen) was used according
to the manufacturer’s protocol.
Wnt conditioned medium (WNT-CM)
Wnt-CM was prepared by collecting the supernatants from L/Wnt3a
cells stably expressing WNT3a. The collected WNT-CM was applied to
293/TOPFlash cells, which was then subjected to luciferase assay to
determine the Wnt activity.
Reporter assay
The chloramphenicol acetyl transferase (CAT) reporter plasmid of the
ATF3 promoter was described previously (Bandyopadhyay et al,
2006a). Briefly, 48h after transfection of the CAT reporter plasmids
DNAs, cells were collected and then subjected to CAT assay. The
reaction was done and acetylated [
14C] chloramphenicol was
quantified with a Phosphor Imager (Packard Instrument, Meriden,
CT). For TOPflash assay, the TOPflash reporter plasmid was transfected
into cells. The luciferase activities were then measured by using Dual-
Luciferase Reporter Assay System (Promega, Madison, MI) and a
Luminometer (Berthold Detection Systems, Huntsville, Alabama). For
each transformation experiment, the Renilla expression plasmid
phRG-TK (Promega) was co-transfected as an internal control and
the promoter activities were normalized accordingly. Because WB1-1
series are luciferase expressing cell lines, we constructed TOPRenilla
plasmid, in which firefly luciferase reporter was replaced by Renilla
luciferase, and TOPRenilla assay was performed. When appropriate, a
GFP-expressing plasmid was co-transfected into cells as an internal
control.
Chromatin immunoprecipitation assay
PC3mm/Tet/Flag-NDRG1 cells were cultured in T75 flasks and fixed
with 37% formaldehyde for 10min at room temperature. To stop the
reaction, 125mM glycine was added to the culture medium, and the
cells were washed with phosphate buffered saline (PBS) and
harvested. Cells were then suspended in cell lysis buffer (5mM PIPE,
85mM KCl, 0.5% Nonidet P-40) and homogenized with a type A
Dounce homogenizer. The cell nuclei were collected and lysed with
Nuclei lysis buffer (50mM Tris–HCl, 10mM EDTA (ethylenediamine-
tetraacetic acid), 1% SDS (sodium dodecyl sulfate)).The chromatin was
sonicated on ice to an average length of 400bp.The sample was then
centrifuged at 48C and the precipitates were resuspended in ChIP
dilution buffer (16.7mM Tris–HCl, 167mM NaCl, 1.1% Triton X-100,
0.01% SDS). After pre-clearing the sample with Protein G agarose
beads (Dynal Biotech, Invitrogen, Carlsbad, California) followed by brief
centrifugation, the supernatant was transferred to a new tube and
anti-b-catenin (Santa Cruz) antibody was added. After overnight
incubation at 48C, Protein G agarose beads were added, and the
sample was incubated for 3h at 48C. Beads were then washed with
washing buffer (100mM Tris–HCl, 500mM LiCl, 1% NP-40, 1%
deoxycholic acid), and DNA-protein complexes were eluted with
Elution buffer (100mM NaHCO3, 1% SDS). DNA-protein was de-
crosslinked followed by phenol extraction, and the purified DNA was
subjected to qPCR using both specific F1R1 (50-CCCTTCCTCCGCTCCG-
TTCGG-30 and 50-CCTGGCTGCGTGCGACTGTGGC-30) and non-specific
primers F2R2 (50-TACCACTCGCCCTAGTTTC-30 and 50-GTGTCCAAAGT-
CACCCTTCG-30) for the b-catenin/TCF binding sequence of the
ATF3 promoter. The qPCR products were also visualized after
electrophoresis on 8% acrylamide gel followed by staining with
ethidium bromide.
Adhesion assay
Mouse lung microvascular endothelial cells were grown to confluence
in 24-well plates. Before seeding the tumour cells, mLMVECs
monolayers were washed three times with PBS. Tumour cells were
stained by CellTracker Green CMFDA (Invitrogen) for 30min and
briefly trypsinized and counted. 2 10
5 cells tumour cells were then
seeded in each well, and allowed to adhere to the monolayer for
30min. Plates were washed three times, and subjected to a fluorescent
microscopy to count the number of cells. Alternatively, if cells expressed
luciferase, they were trypsinized and lysates were subjected to
luciferase activity assay using the Dual-Luciferase Reporter Assay
System.
Invasion and wound healing assays
For invasion assays, 1 10
5 cells were seeded in a Matrigel-coated
upper chamber (BD Biosciences) in serum-free media, and 20% foetal
bovine serum was added to the bottom chamber followed by
incubation for 24h at 378C. The upper chamber was removed, and
the cells that invaded through the membrane were stained with
tetrazolium dye and counted under microscope. Triplicate tests were
performed in each case. For wound healing assays, tumour cells
were pulsed with 5mM CellTracker Green CMFDA (Invitrogen) for
30min, and seeded in a 6-well plate and cultured to a confluent
monolayer. The ‘scratch’ was introduced by scraping the monolayer
with a p200 pipette tip and marked for orientation and photographed
by a fluorescent microscope immediately and after 24-, 48- and
72h.
Lung extravasation assay
Tumour cells were pulse labelled by incubating with 5mM CellTracker
Green CMFDA (Invitrogen) for 30min and inoculated into the
circulation of mice through tail vein. Mice were sacrificed 2- or 48h
later, and lungs were inflated with PBS, soaked with 30% sucrose in
PBS þ2mM MgCl2 at 48C overnight, they were then embedded in OCT
for frozen sectioning. Lung vasculature was visualised by rhodamine-
conjugated lectin and tumour cells in the lung were visualised under
fluorescent and confocal microscope.
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Results are reported as mean SD (or mean SEM) as indicated in
figure legends. Statistical significance was determined by two-sided
Student’s t-test. Oncomine and GEO database were used to evaluate
the clinical relevance of NDRG1, Wnt ligand (Wnt1, Wnt2 and Wnt3),
LRP6 and ATF3 in prostate and breast cancers. For clinical cohort
dataset analysis, we downloaded five publicly available prostate and
breast cancer data sets including Taylor (GSE21034, n¼218),
Lapointe (GSE3933, n¼112), Yu (GSE6919, n¼60) and MSK
(GSE2603, n¼82, GSE14020, n¼57). The data was log-2-trans-
formed, with the median set as 0 and SD set as 1. Each patient was
assigned to have positive or negative expression of each gene and was
matched with relapse-free survival data (GSE6919) and metastasis-
free survival data (GSE21034 and GSE2603). The gene expressions in
primary tumour (GSE3933 and GSE 2603) or metastatic sites
(GSE14020) in patients who have either metastatic or non-metastatic
disease were compared by Box-and-whisker plot analysis and
evaluated by Mann–Whitney test. The association between genes
and clinical outcomes was calculated by Pearson x
2 test. The Kaplan–
Meier method was used to calculate the overall survival rate, and
prognostic significance was evaluated by the Log-rank test. Univariate
or multivariate analysis for the prognostic value of gene signatures
was performed by the Cox proportional hazard-regression model. For
all statistical analysis, Prism and SPSS software were used.
Immunohistochemistry
Immunohistochemical analysis on paraffin-embedded, surgically
resected specimens of prostate and breast was carried out using
anti-NDRG1 rabbit polyclonal antibody (1:100), anti-ATF3 rabbit
polyclonal antibody (1:500, Santa Cruz, CA) and anti-b-catenin rabbit
polyclonal antibody (1:500, Santa Cruz, CA). Briefly, sections were
deparaffinized, rehydrated and heated at 808C for 20min in 25mM
sodium citrate buffer (pH 9) for antigen exposure. They were then
treated with 3% H2O2 to block endogenous peroxidase activity and
further incubated with primary antibody for 1h at 248C. After
washing with Tris-buffered saline/0.1% Tween-20, the sections were
incubated with horseradish peroxidase-conjugated rabbit-specific IgG
(Dako Corp.). The sections were washed extensively and DAB substrate
chromogen solution was applied followed by counterstaining with
hematoxylin.
Animal studies
Four to six weeks old SCID mice (Harlan Sprague-Dawley, Indianapolis,
IN) were used for the spontaneous metastasis studies. Viable tumour
cells were resuspended in 50:50 solutions of PBS and Matrigel, and
5 10
5 cells were injected into the thoracic mammary fat pad. The
primary tumour and metastasis outgrowth were monitored twice a
week using bioluminescent imaging (BLI) with IVIS
1 Imaging System
(Xenogen, Hopkinton, MA). After 6 weeks, mice were sacrificed and
lungs and bones were extracted, the metastatic lesions on the
individual lungs and bones were evaluated by ex vivo imaging and
histologic analysis. Tumour growth was also monitored by measuring
the tumour length (L) and Width (W). Tumour volume was calculated
as (widthþlength)/2 width length 0.5236. Dp44mT (Sigma, Mo)
was dissolved in 15% propylene glycol (Fisher) in 0.9% saline, and
injected intravenously into mice over five consecutive days. All protocols
were approved by the Southern Illinois Universtiy Institutional Review
Board. For histological analysis, tumour and/or lungs were excised, fixed
in 10% neutral-buffered formalin and embedded in paraffin.They were
then subjected to immunocytofluorescence staining with specific
antibodies or staining with hematoxylin and eosin (H&E, American
Histolabs Inc.).
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The paper explained
PROBLEM:
Majority of cancer deaths is attributed to metastatic disease;
however, the exact molecular mechanism of this disease is
largely unknown due to its intricate pathological process. A
potential loss of metastasis suppressor has been implicated to
contribute to this pathway. Previously, we showed that NDRG1 is
a metastasis suppressor in prostate and breast cancers. Herein,
we addressed the question how NDRG1 gene exerts its
metastasissuppressorfunction. Duringthe course of our study to
address this question, we serendipitously found that NDRG1 is
capable of modulating Wnt-b-catenin signalling, which is an
evolutionally well-conserved signalling pathway in normal
development.
RESULTS:
Herein,we reportedthatthetumourmetastasissuppressorgene,
NDRG1, pleiotropically suppresses tumour metastasis through
modulation of the canonic Wnt-b-catenin signalling.
Importantly, we found that Wnt/NDRG1 signature has a strong
predictable value for recurrence-free survival of cancer patients.
Restoring NDRG1 expression by a small molecule compound
significantly suppressed the capability of otherwise highly
metastatic tumour cells to thrive in the circulation and distant
sites in vivo.
IMPACT:
We have elucidated the molecular mechanism by which NDRG1
functions as a metastasis suppressor. Our findings not only
revealedanintriguingcross-talk mechanismbetweenthecritical
developmental signalling (Wnt) and a metastasis suppressor
gene (NDRG1), but also provided the molecular basis by which
Wnt signalling modulates tumour progression. We also found a
unique signature of Wnt/NDRG1 pathway which has strong
predictable value for recurrence-free survival of cancer patients.
We believe that our newly discovered mechanism of metastasis
suppression by NDRG1 opened a window of opportunity to
identify a novel therapeutic target for metastatic disease.
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